导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.39% | 2918/4773 |
| 近一周 | -1.99% | 1030/5462 |
| 近一月 | -3.80% | 1968/5421 |
| 近一季 | -7.60% | 2464/5209 |
| 近半年 | -3.99% | 2389/4920 |
| 近一年 | -0.84% | 2785/4366 |
| 近两年 | 43.22% | 1724/2954 |
| 近三年 | 24.49% | 1302/2253 |
| 成立以来 | 16.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.41% 3189/4961 |
11.89% 2275/5312 |
- - |
- - |
| 2025 | 18.45% 2316/4813 |
-0.98% 2513/3635 |
1.63% 2254/4076 |
17.84% 2422/4524 |
-0.11% 2366/4813 |
| 2024 | 14.95% 982/3463 |
2.01% 831/2808 |
-1.60% 1082/3014 |
15.52% 1694/3129 |
-0.87% 1535/3463 |
| 2023 | -10.72% 1327/2656 |
3.33% 1217/2280 |
-4.98% 1334/2385 |
-3.30% 890/2515 |
-5.96% 1573/2655 |
| 2022 | -18.54% 724/2207 |
-13.99% 888/1919 |
6.57% 662/2016 |
-12.21% 671/2113 |
1.24% 1332/2208 |
| 2021 | 4.69% 568/1822 |
-2.65% 685/1255 |
8.33% 633/1330 |
-2.57% 582/1466 |
1.89% 762/1822 |
| 2020 | - - |
- - |
- - |
- - |
12.86% 422/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 摩根MSCI中国A股ETF联接C VS. 长安沪深300非周期A(740101) |